2022: A year of great achievements for Hofseth BioCare
With the New Year in sight, now is the perfect time to reflect on the past 12 months, while looking to the year ahead. For Hofseth BioCare (HBC), 2022 has been a year filled with accomplishments and accolades; from securing new FDA-approved health claims and NDI acknowledgement for our entire product portfolio to making significant advances with our scientific research and receiving prestigious awards for our efforts. This has all contributed towards our greater goal of shaping a naturally-inspired nutraceutical landscape, steeped in scientific evidence.
Here, we outline our top highlights from 2022 - spotlighting some of the key milestones we’ve reached on our journey to improving health, wellbeing and quality of life of consumers worldwide.
AWARDS & ACCREDITATIONS
HBC recognised for its innovative ingredients and sustainable processes
HBC was crowned as the winner of the Ingredient and Raw Materials category at the Ringier Technology Innovation Awards in China. HBC’s ProGo® bioactive peptides ingredient was commended for its myriad of nutritional benefits including collagen for skin health, as well as its antioxidant properties which have been clinically-proven to sustain overall health and boost energy levels.
In the same year, HBC was also named the Best Sustainable Company and Most Innovative Human Medical Nutrition Ingredient Producer of 2022 in recognition of 15 years of pioneering research, product development, and zero-waste business model.
HBC’s complete ingredient portfolio acknowledged as NDIs by the FDA
September brought exciting news for HBC as ProGo® joined both CalGo® and OmeGo® in being acknowledged as a New Dietary Ingredient (NDI) by the US Food and Drug Administration (FDA) – the highest safety rating and attestation available. This means that HBC’s full product portfolio has now achieved the notification, cementing our position in the nutraceutical market.
Not only that but all three of HBC’s flagship ingredients have achieved a myriad of new and unique US Food and Drug Administration (FDA) structure function claims, the latest of which include energy and vitality, gut health & gut inflammation, immunity and antioxidant claims for ProGo® and cardiovascular and potent antioxidant claims for OmeGo® - stay tuned for the big reveal in 2023!
ADVANCES IN RESEARCH & DEVELOPMENT
Science from the Stanford University School of Medicine shows benefits of ProGo® for gut health
More exciting news came along for ProGo® in October, as the Stanford University School of Medicine announced the findings of a new study exploring the efficacy of its bioactive peptides in restoring and maintaining gut health. The research found that ProGo® helped to alleviate inflammatory cell infiltrates and oxidative stress, both of which are drivers of many digestive diseases. This collaboration was a great stride forward for HBC and news travelled far and wide, featuring in several leading nutraceutical publications, such as NutraIngredients, Nutrition Insight & Nutritional Outlook.
New evidence supports OmeGo® ‘s benefits for immune health
OmeGo® also came under the spotlight in November thanks to a Biomedicines animal study which concluded this nutraceutical ingredient shows great promise in resolving inflammation associated with respiratory health issues, such as asthma. This news reached many international publications such as Nutritional Outlook, Nutrition Insight & NutraIngredients. Further studies into this unique ingredient’s ability to resolve acute inflammation and swelling, and its promise to support joint health, will be revealed in 2023.
Bone health study finds CalGo® to be significantly more absorbable than calcium carbonate
Earlier in the year, HBC’s unique calcium-collagen complex CalGo® was studied for its absorbing abilities and found it to be 6 times more absorbable than calcium carbonate. The study also found that CalGo® delivers complete bone matrix support, from better cartilage function and joint health to increased bone strength and density.
More results due from completed studies and new trials starting in 2023 …
At HBC, we are committed to pushing the boundaries of science and unlocking the true potential of our clinically-important ingredients. We have several studies scheduled for 2023 and beyond, aimed at further evidencing and uncovering the broad range of health benefits that can be realised from our ingredients, including:
- Joint health studies focusing on CalGo ® and OmeGo®
- Beauty from within studies exploring the benefits of ProGo® for anti-aging and skin health
- Post menopausal study on ProGo® to highlight the benefits on body metabolism, energy and wellbeing
- Covid-19 study results to demonstrate the immune health benefits provided by OmeGo®
HBC IN THE NEWS
Head of R&D featured in The Guardian
HBC’s Head of Medical R&D, Dr. Crawford Currie, was featured in The Guardian – reaching a readership of almost 32 million people! The feature outlined the extensive health benefits associated with collagen; from supporting wrinkled skin and painful muscles to alleviating osteoarthritis symptoms. Read the full article here.
JOIN US AS WE LOOK AHEAD TO 2023…
This year we’ve also had the opportunity to join industry leaders at several international trade shows to explore new avenues for innovation and collaboration with key players across the globe; from Vitafoods Europe in Geneva to the Blue Food Innovation Summit in London, FiAsia in Jakarta, SupplySide West in Las Vegas, InVitality in Milan and FiEurope Paris. We look forward to revisiting some of these prestigious tradeshows in 2023. If you’re also planning to attend, please get in touch to meet us there!
We’re proud of the progress we’ve made this year and excited to see what 2023 has in store. Thank you for your ongoing support in helping us develop pioneering and sustainable product innovations to transform the lives of many for the better. Happy New Year!